Skip to main content
Premium Trial:

Request an Annual Quote

Cardinal Health to Distribute Qiagen MDx Products to Small, Mid-sized US Hospitals

NEW YORK (GenomeWeb News) – Qiagen announced after the close of the market on Monday that Cardinal Health will make Qiagen's molecular diagnostics products available to small and mid-sized hospitals in the US not covered by Qiagen's own sales channels.

Based in Dublin, Ohio, Cardinal Health distributes pharmaceuticals and medical products to healthcare providers and has annual sales of $103 billion.

The deal is anticipated to create critical mass for the distribution of molecular diagnostic products to the approximately 5,000 community hospitals in the US, "thereby supporting the adoption of in-house molecular diagnostic testing among smaller US hospitals," Qiagen said in a statement.

Citing statistics from the American Hospital Association, Qiagen said that only about 10 percent of US hospitals perform molecular diagnostics.

"We are very excited about this relationship with Cardinal Health, as we expect to create access to Qiagen products for hospitals of all sizes, where before they were primarily available to large hospitals and reference laboratories," Bernd Uder, senior vice president of global sales for Qiagen, said in a statement.

Qiagen said it will provide application and technical support to Cardinal Health customers.

Financial and other terms of the deal were not disclosed.

Molecular diagnostics products available in the US from Qiagen include its Rotor-Gene Q MDx platform, which was recently cleared by the US Food and Drug Administration, along with the artus Influenza A/B assay. The company intends to obtain FDA approval for the entire QIAsymphony RGQ system, including the Rotor Gene Q series instruments and a pipeline of corresponding tests under development.

Last week, Qiagen announced that revenues for its first quarter rose 12 percent year over year.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.